Ally Perlina, PhD

Ally Perlina is a proven executive leader who has dedicated nearly two decades of industry experience to solving challenging problems in precision medicine, health-tech, and pharmaceutical fields to improve human health with molecular-level personalization. She is a visionary innovator with a track record of translating complex data into actionable insights delivered as scalable AI products by integrating analytics with systems biology and knowledge management techniques.

As Chief Translation Science Office (CTSO) of Viome, Ally developed unique methodology for automated pathway analysis personalizing nutraceuticals at scale. Previously, at Human Longevity, Inc. (HLI), co-founded by Craig Venter, Ally spearheaded the Comprehensive Cancer Program creating novel analytics for clinical decision support. At tumor boards, she provided mechanistic rationale for drug and trial prioritization. Ally’s experience also includes working with top pharma at a systems biology startup acquired by Thomson Reuters, researching cancer at SBP, working at a CLIA lab acquired by Quest, and focusing on clinical genomics of brain tumors in her graduate training at the UCLA Ph.D. program in Human Genetics where she also earned her M.S. degree. Ally received her B.S. in Biochemistry and Cell Biology from UCSD. She is a published author and an inventor on several patents.